Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

被引：3
|
作者：
Allen, Pamela [1 ]
Chen, Qing C. [2 ]
Lu, Xinyan [2 ]
O'Shea, Kaitlyn [3 ]
Chmiel, Joan [4 ]
Sukhanova, Madina [2 ]
Slonim, Liron Barnea [2 ]
Savas, Hatice [5 ]
Mou, Eric [6 ]
Pro, Barbara [7 ]
Evens, Andrew M. [8 ]
Palmer, Brett Alan [7 ]
Advani, Ranjana [9 ]
Gordon, Leo I. [7 ]
Winter, Jane N. [7 ]
机构：
[1] Emory Univ, Winship Canc Inst, Decatur, GA USA
[2] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Northwestern Univ, Dept Biostat, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA
[6] Stanford Univ, Dept Med, Div Oncol, Palo Alto, CA USA
[7] Northwestern Univ, Div Hematol & Oncol, Chicago, IL 60611 USA
[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[9] Stanford Canc Inst, Saul A Rosenberg Prof Lymphoma, Dept Med, Div Oncol, Stanford, CA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147042
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
231
引用
收藏
页数：4
相关论文
共 44 条
  • [21] Interim analysis results of a phase II trial of single agent ofatumumab in the treatment of relapsed/refractory mantle cell lymphoma
    Furtado, M. V.
    Riordan, R.
    Dyer, M. J. S.
    Rule, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 47 - 47
  • [22] TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA WITH 4 CYCLES OF BEACOPP ESCALATED FOLLOWED BY 4 CYCLES OF BEACOPP BASELINE: LONG-TERM RESULTS FROM A SINGLE CENTRE
    Stepankova, P.
    Belada, D.
    Sykorova, A.
    Maly, J.
    HAEMATOLOGICA, 2010, 95 : S24 - S25
  • [23] Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database
    Winter, Allison
    Liu, Nicholas
    Surinach, Andy
    Fanale, Michelle A.
    Yu, Kristina S.
    Narkhede, Mayur
    BLOOD, 2022, 140 : 8054 - 8055
  • [24] BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: A single center comparative analysis of efficacy and toxicity
    Kim, Jeong Eun
    Lee, Dae Ho
    Yoo, Changhoon
    Kim, Shin
    Kim, Sang-We
    Lee, Jung-Shin
    Park, Chan Jeong
    Huh, Jooryung
    Suh, Cheolwon
    LEUKEMIA RESEARCH, 2011, 35 (02) : 183 - 187
  • [25] Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study
    Mauz-Koerholz, Christine
    Beishuizen, Auke
    Vinti, Luciana
    Ceraulo, Antony
    Michel, Gerard
    Cepelova, Michaela
    Fagioli, Franca
    Alvarez, Constantino Sabado
    Cepelova, Michaela
    Fagioli, Franca
    Alvarez, Constantino Sabado
    Ducassou, Stephane
    Buffardi, Salvatore
    Catalan, Maitane Andion
    Hoppe, Brad
    Keller, Frank
    Kelly, Kara M.
    Roth, Lisa Giulino
    Landman-Parker, Judith
    Shen, Juan
    Pillai, Pallavi
    Daw, Stephen
    BLOOD, 2023, 142
  • [26] THE ROLE OF HIGH DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN PATIENTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Dahan-Shriki, D.
    Gafter-Gvili, A.
    Vidal, L.
    Raanani, P.
    Shpilberg, O.
    Gurion, R.
    HAEMATOLOGICA, 2014, 99 : 696 - 696
  • [27] Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment
    Timmerman, John
    Lavie, David
    Johnson, Nathalie A.
    Avigdor, Abraham
    Borchmann, Peter
    Andreadis, Charalambos
    Bazargan, Ali
    Gregory, Gareth P.
    Keane, Colm
    Tsoran-Rosenthal, Inna
    Vucinic, Vladan
    Zinzani, Pier Luigi
    West, Rachel Marceau
    Pillai, Pallavi
    Nahar, Akash
    Herrera, Alex F.
    BLOOD, 2022, 140
  • [28] HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS
    Brillant, C.
    Schwarzer, G.
    Bohlius, J.
    Greb, A.
    Trelle, S.
    Haioun, C.
    De Souza, A.
    Gisselbrecht, C.
    Intragumtornchai, T.
    Kaiser, U.
    Kluin-Nelemans, C.
    Martelli, M.
    Milpied, N.
    Verdonck, F.
    Vitolo, U.
    Engert, A.
    Schulz, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 392 - 392
  • [29] Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN plus AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
    Lee, Hun
    Flinn, Ian W.
    Melear, Jason
    Ramchandren, Rod
    Friedman, Judah
    Burke, John M.
    Linhares, Yuliya
    Gonzales, Paul Alan
    Raval, Mihir
    Chintapatla, Rangaswamy
    Feldman, Tatyana
    Yimer, Habte
    Islas-Ohlmayer, Miguel
    Dean, Asad
    Rana, Vishal
    Gandhi, Mitul
    Renshaw, John
    Ho, Linda
    Fanale, Michelle A.
    Guo, Wenchuan
    Yasenchak, Christopher A.
    BLOOD, 2022, 140
  • [30] A Single-Centre Analysis by Intention to Treat with High Dose Chemotherapy and Autologous Stem Cell Rescue Following Second-Line Treatment In Patients with Hodgkin Lymphoma
    Greaves, Paul
    Wilson, Andrew
    Matthews, Janet
    Brown, Daniel L. P.
    Montoto, Silvia
    Gribben, John G.
    Lister, Andrew
    BLOOD, 2010, 116 (21) : 989 - 990
12345